BEVERLY HILLS, Calif., Aug. 11 /PRNewswire-FirstCall/ -- OXIS INTERNATIONAL, INC. (OTC Bulletin Board: OXIS, Paris: OXI) announced today the addition of Dr. Stephen Coles as the newest member to its Scientific Advisory Board. The addition of Dr. Coles given his extensive research in the area of DNA, RNA and anti-aging will prove to be extremely beneficial in the company's product rollout. His vast body of clinical research highlighted vital information as to the importance of reducing free radicals and implementing antioxidant defense systems that will eventually curtail premature aging.

Along with having extensive knowledge of the effects of Oxidative Stress, Stem Cell Technology and Medical Image Processing, Dr. Coles is Co-Founder and Director of the Los Angeles Gerontology Research Group (GRG) and Director of the Supercentenarian Research Foundation where much of his research is related to Oxidative Stress. He has made valuable contributions in the science world, serving in numerous positions such as Chief Technologist for Predicate Logic, Inc., Chief Technologist Computer Sciences Corporation, while also establishing two patents in the science realm. In addition to this, he served as Assistant Researcher in the Department of Surgery at UCLA's David Geffen School of Medicine and has specified program requirements for seven major software systems which include Clinical Medicine and Radiology.

Currently, Dr. Coles is a Lecturer in the Department of Chemistry and Biochemistry (Molecular Biology Institute) at UCLA. Over the years Dr. Coles has lectured at Stanford, UC Berkeley, UCLA, USC and the California Institute of Technology. He's published over 150 scientific papers including many on anti-aging Oxidative Stress.

Dr. Coles earned his B.S. in Electrical Engineering from Rensselaer Polytechnic Institute, his Master's in Mathematics from the Carnegie Institute of Technology, and his Ph.D. from Carnegie-Mellon University in Systems and Communication Sciences. Dr. Coles attended Medical School at Stanford University before going on to complete his Clinical Internship at Jackson Memorial Hospital of the University Of Miami School Of Medicine.

About OXIS International, Inc.

OXIS International, Inc. develops technologies and products to research, diagnose, treat and prevent diseases of oxidative stress/inflammation associated with damage from free radical and reactive oxygen species (ROS). The company holds the rights to several therapeutic classes of compounds in the area of oxidative stress, and has focused commercialization programs that include SOD (superoxide dismutase), MPO (myeloperoxidase), GPx (glutathione peroxidase), as well as a highly potent antioxidant, Ergothioneine, that may be sold over-the-counter (OTC) as a dietary supplement.

Forward-Looking Statement

This press release contains forward-looking statements that involve numerous risks and uncertainties. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements as a result of certain factors, including those set forth in the Company's filings with the Securities and Exchange Commission.

SOURCE OXIS International, Inc.